1993
DOI: 10.1021/jm00074a013
|View full text |Cite
|
Sign up to set email alerts
|

Trisubstituted pyridine leukotriene B4 receptor antagonists: synthesis and structure-activity relationships

Abstract: A series of trisubstituted pyridines have been prepared that exhibit in vitro leukotriene B4 (LTB4, 1) receptor antagonist activity. Previous disubstituted pyridines from these labs showed high affinity for the LTB4 receptor but demonstrated agonist activity in functional assays (e.g., 2, Ki = 1 nM). Compound 4, the initial lead compound of this new series, showed only modest affinity by comparison (Ki = 282 nM); however, 4 was a receptor antagonist with no demonstrable agonist activity up to 10 microM. Subseq… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
17
0

Year Published

1994
1994
2017
2017

Publication Types

Select...
6
1
1

Relationship

0
8

Authors

Journals

citations
Cited by 16 publications
(17 citation statements)
references
References 11 publications
0
17
0
Order By: Relevance
“…1.13.11.34) inhibitor, SB 210661 ( McLoughlin et al ., 1998 ), and a cysteinyl leukotriene (CysLT 1 ) receptor antagonist, pranlukast (SB 205312, ONO‐1078) ( Obata et al ., 1992 ; Fujiwara et al ., 1993 ; Taki et al ., 1994 ), in order to evaluate the role of CysLT in bronchial responsiveness and airway wall remodelling. In addition, the potential contribution of another 5‐LO product, leukotriene B 4 , in these processes has been studied using a specific LTB 4 (BLT) receptor antagonist, SB 201146 ( Daines et al ., 1993 , 1996 ).…”
Section: Introductionmentioning
confidence: 99%
“…1.13.11.34) inhibitor, SB 210661 ( McLoughlin et al ., 1998 ), and a cysteinyl leukotriene (CysLT 1 ) receptor antagonist, pranlukast (SB 205312, ONO‐1078) ( Obata et al ., 1992 ; Fujiwara et al ., 1993 ; Taki et al ., 1994 ), in order to evaluate the role of CysLT in bronchial responsiveness and airway wall remodelling. In addition, the potential contribution of another 5‐LO product, leukotriene B 4 , in these processes has been studied using a specific LTB 4 (BLT) receptor antagonist, SB 201146 ( Daines et al ., 1993 , 1996 ).…”
Section: Introductionmentioning
confidence: 99%
“…The ring transformation proceeded via Michael addition of the conjugate base of 4 to the lactones 3a-h at position 6 followed by intramolecular cyclization and subsequent loss of CO 2 . Oxidation of the methylthio group to the methylsulfonyl group was achieved in 58-75% yield by stirring an equimolar mixture of 5e and 5g with meta-chloroperbenzoic acid (m-CPBA) 49 in dry dichloromethane for 30-60 minutes at ambient temperature to afford the methyl 8-(methylsulfonyl)-2-phenyl-6-aryl-4,5dihydro-2H-benzoije]indazole-9-carboxylates 6a and 6b (Scheme 1). All the new synthesized derivatives of 2Hbenzoije]indazole-9-carboxylates (5a-c, e, f, h and 6a, b) were characterized by spectroscopic analyses.…”
Section: Resultsmentioning
confidence: 99%
“…PPE, PFBT ( M n ∼ 17 000–23 000), and PSMA ( M n ∼ 1900, 25% maleic anhydride) polymers were purchased from Sigma-Aldrich while PFBTDBT ( M n ∼ 12 000) was synthesized according to our previously published work . Spiropyran derivatives were synthesized according to previously published reports, ,, and thus, their synthetic procedures were not described herein. Other compounds were synthesized with modified procedures, and the appropriate literature was cited for each compound.…”
Section: Methodsmentioning
confidence: 99%
“…For the preparation of PSMA-SP(B), 2 μL of 2-butyl-1octanol was added in the reaction. 34,37 The detailed synthesis of Py-Bips has been reported previously. 2,3 Briefly, 0.1 g (0.29 mmol) of 3-(3,3,6′-trimethylspiro-[indoline-2,2′-pyrano[3,2-b]pyridin]-1-yl)propan-1-ol was dissolved in 5 mL of dry THF, and then, 0.2 mL (3.2 mmol) of iodomethane was added dropwise.…”
Section: ■ Experimental Sectionmentioning
confidence: 99%